OnKure Therapeutics, Inc. Overview
Pro stress-test →OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class precision medicines that target biologically validated drivers of cancers. The company uses a structure-based drug design platform to build a robust pipeline of tumor-agnostic candidates.
Strategic Profile
Pro stress-test →OnKure is discovering and developing a portfolio of highly mutant-selective PI3Kα inhibitors with the goal of improving efficacy and safety by fully inhibiting the mutant oncogene while sparing the wild-type enzyme in normal tissues. The company is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program.
Competitive Landscape
Pro stress-test →While novel drugs targeting PI3Kα have been approved for treatment, the lack of mutant selectivity of these therapeutics drives considerable on-target toxicity. OnKure differentiates through mutant-selective inhibition, competing against existing PI3K inhibitors from larger pharma companies while addressing an unmet clinical need in precision oncology.
Industry Context
OnKure Therapeutics, Inc. operates in Clinical-Stage Biopharmaceuticals / Oncology.
Key facts
Founded: 2024 · Headquarters: Boulder, Colorado, USA · Revenue: N/A · Market cap: $36.7M